This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muss, H. B. Articles by Aapro, M. Search for Related Content PubMed PubMed Citation Articles by Muss, H. B. Articles by Aapro, M. Social Bookmarking                            What's this?

Adjuvant Therapy in the Elderly: Making the Right Decision

Hyman B. Muss, Laura Biganzoli, Daniel J. Sargent, Matti Aapro

From the University of Vermont and Vermont Cancer Center, Burlington, VT; Department of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN; Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Prato, Italy; and the Multidisciplinary Oncology Institute, Genolier, Switzerland

Address reprint requests to Hyman B. Muss, MD, University of Vermont and Vermont Cancer Center, 1 S Prospect St, UHC Campus, St Joseph 3400, Burlington, VT 05401; e-mail: hyman.muss{at}uvm.edu

Adjuvant chemotherapy has led to improvements in relapse-free and overall survival in patients with breast, colon, and non–small-cell lung cancer, yet many older patients are not offered these potentially life-saving treatments. Moreover, older patients have been either excluded or under-represented in most adjuvant trials, limiting the generalizability of these treatments to older populations. Limited data in elders suggest that older patients derive significant benefits from adjuvant therapies provided they have life expectancies exceeding 5 years. Making treatment decisions in elders is challenging. Many have major comorbidities that may substantially limit life expectancy and minimize or negate the benefits of adjuvant chemotherapy. In this review, we discuss the potential benefits of adjuvant treatment in older patients with solid tumors with a focus on general principles involved in the selection of adjuvant therapy for patients with breast, colon, and non–small-cell lung cancer. In addition, we discuss the role of comorbidity and how it factors in treatment decisions. Finally, we discuss future research directions and funding for elders with cancer.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Papamichael, R. Audisio, J.-C. Horiot, B. Glimelius, J. Sastre, E. Mitry, E. Van Cutsem, M. Gosney, C.-H. Kohne, and M. Aapro Treatment of the elderly colorectal cancer patient: SIOG expert recommendations Ann. Onc., January 1, 2009; 20(1): 5 - 16. [Abstract] [Full Text] [PDF]

				M. Extermann and H. B. Muss Conducting Clinical Trials for Patients Who Are Frail or Elderly ASCO Educational Book, January 1, 2009; 2009(1): 289 - 293. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, L. Balducci, and M. Aapro Geriatric Oncology: A Field Coming of Age J. Clin. Oncol., May 10, 2007; 25(14): 1821 - 1823. [Full Text] [PDF]